Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease burden and quality of life in caregivers of infants with RSV lower respiratory tract infections in Japan.

Japanese journal of infectious diseases·2026
Same author

Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF.

Expert review of vaccines·2026
Same author

Clinical features and trends of severe paediatric group A streptococcal infections in Japan in the post-COVID-19 pandemic era.

Epidemiology and infection·2026
Same author

Risk of developing pneumococcal disease in individuals under 19 years of age with chronic medical conditions: a retrospective cohort study using a Japanese insurance claims database.

BMJ open·2026
Same author

Spatial and temporal variability of respiratory syncytial virus disease seasonality in Japan, 2012-2024.

Pediatrics international : official journal of the Japan Pediatric Society·2025
Same author

First report of pediatric bacterial meningitis caused by Haemophilus influenzae serotype e in Japan: A case report.

Pediatrics international : official journal of the Japan Pediatric Society·2025

Related Experiment Video

Updated: May 29, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Pneumococcal vaccine].

Naruhiko Ishiwada1

  • 1Department of Pediatrics, Chiba University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 20, 2011
PubMed
Summary

Two pneumococcal vaccines, PPV23 and PCV7, are available in Japan for preventing serious infections. Wider use of these vaccines is crucial for protecting children and adults from pneumococcal disease.

Area of Science:

  • Microbiology
  • Immunology
  • Public Health

Context:

  • Streptococcus pneumoniae causes significant systemic and respiratory infections globally.
  • Pneumococcal disease disproportionately affects young children and the elderly.
  • Japan currently has two available pneumococcal vaccines: PPV23 for adults and PCV7 for children.

Purpose:

  • To review the current status and expected benefits of pneumococcal vaccines in Japan.
  • To highlight the potential of PPV23 and PCV7 in reducing pneumococcal disease burden.

Summary:

  • Streptococcus pneumoniae is a leading cause of invasive and respiratory infections across all age groups.
  • The 23-valent pneumococcal polysaccharide vaccine (PPV23) targets adults for invasive pneumococcal disease and pneumonia.

More Related Videos

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Experiment Videos

Last Updated: May 29, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

  • The 7-valent pneumococcal conjugate vaccine (PCV7) targets young children for invasive pneumococcal disease and respiratory tract infections.

    • Impact:

    • Widespread adoption of PPV23 and PCV7 is anticipated to significantly decrease pneumococcal disease incidence in Japan.
    • Increased vaccination coverage can lead to reduced healthcare costs and improved public health outcomes.
    • This review underscores the importance of public health initiatives for broader vaccine implementation.